Why the study?
Does melatonin reduce arterial pressure and improve vascular pathways in spontaneously hypertensive rats?
Does melatonin reduce arterial pressure and improve vascular pathways in spontaneously hypertensive rats?
Chronic melatonin treatment exerts antihypertensive and bradycardic effects in spontaneously hypertensive rats, likely mediated by improved vascular nitric oxide synthase pathway activity.
Answers are grounded in this paper and cite their sources.
Melatonin shows promise in hypertensive rat models; leaves open translation to human therapy.
OBJECTIVE: To investigate the effect of a chronic treatment with melatonin on arterial pressure and a possible improvement of the vascular muscarinic and NO synthase (NOS) pathways in spontaneously hypertensive rats (SHR) and Wistar-Kyoto (WKY) rats. DESIGN AND METHODS: Mean arterial pressure (MAP), systolic (SBP), diastolic blood pressure (DBP), and heart rate (HR) were evaluated in conscious rats treated with 30 mg/kg per day of melatonin during 4 weeks. Changes in MAP were evaluated following an intravenous injection of the NOS inhibitor N-omega-nitro-L-arginine methyl ester (L-NAME). Relaxant effects of acetylcholine (Ach), sodium nitroprusside (SNP), and the calcium ionophore A23187 were examined on mesenteric beds and aortic rings with or without treatment with melatonin. RESULTS: Melatonin produced a significant reduction of MAP, SBP, DBP and HR in SHR (P < 0.05). L-NAME increased the MAP of melatonin-treated SHR by the same magnitude as that of WKY rats which was significantly higher than that of non-treated SHR (P< 0.05). Melatonin treatment improved the maximal relaxation of mesenteric arteries to A23187 in SHR (P < 0.001) to the WKY level and caused a slight increment in Ach- and A23187-induced vasodilations in aorta from SHR and WKY rats (P < 0.05). CONCLUSION: The present study showed that melatonin exerted a bradycardic and an antihypertensive action in SHR. The enhancement by melatonin of the endothelium-dependent vasodilation (Ach and/or A23187) in mesenteric artery and aorta from SHR and WKY rats and the higher increase in MAP following L-NAME treatment in melatonin-treated SHR suggest the contribution of an improved vascular NOS pathway activity in the hypotensive effect of melatonin.
No takes yet. Share an insight, caveat, or question.
Girouard et al. (2001) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: